Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high269.75 11/09/17
52 week low138.25 03/01/17
52 week change 15.00 (8.57%)
4 week volume581,732 22/09/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc: Holding(s) in Company TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Rea...

Summit highlights Microbiome Preservation during Ridinilazole treatment

Summit has announced that at ID Week 2017, it presented further positive gut microbiome data of ridinilazole from its ex...

Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017

Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017 Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT HIGHLIGHTS MICROBIOME PRESERVATION DURING RIDINILAZOLE TREATMENT IN EXPLORATORY PHASE 2 CLINICAL TRIAL AT ID WEEK 2017 Oxford, UK, 9 October 2017 - Summit Ther...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 5 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit to present at conference in Saint-Malo

Summit Therapeutics has confirmed that the Company and its collaborators will be presenting at the 22nd International C...

Summit Highlights DMD Biomarker Validation Data at 22nd WMS Congress

Summit Highlights DMD Biomarker Validation Data at 22nd WMS Congress Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT HIGHLIGHTS DMD BIOMARKER VALIDATION DATA AND PHASE 2 CLINICAL TRIAL BASELINE CHARACTERISTICS IN PRESENTATIONS AT 22NDWMS CONGRESS Oxford, UK, 4 October 2017 - Summit Th...

Summit Therapeutics plc : Exercise of Options

Summit Therapeutics plc: Exercise of Options Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 3 October 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announce...

Summit to host R&D day

Summit Therapeutics has confirmed that the Company will host an R&D Day featuring presentations from experts in qu...

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Dilution

    So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...
    14-Sep-2017
    scep
  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
    6-Jul-2017
    bobsson
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.22%
RANGE RES.20%
ROYAL BANK SCOT17%
SIRIUS MINERALS15%
ROCKHOPPER13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM